Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 4.08
ARRY's Cash-to-Debt is ranked lower than
64% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. ARRY: 4.08 )
Ranked among companies with meaningful Cash-to-Debt only.
ARRY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.49  Med: 1.69 Max: No Debt
Current: 4.08
0.49
No Debt
Equity-to-Asset 0.53
ARRY's Equity-to-Asset is ranked lower than
68% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. ARRY: 0.53 )
Ranked among companies with meaningful Equity-to-Asset only.
ARRY' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.55  Med: 0.23 Max: 0.93
Current: 0.53
-1.55
0.93
Debt-to-Equity 0.41
ARRY's Debt-to-Equity is ranked lower than
62% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. ARRY: 0.41 )
Ranked among companies with meaningful Debt-to-Equity only.
ARRY' s Debt-to-Equity Range Over the Past 10 Years
Min: -18.96  Med: -0.31 Max: 18.79
Current: 0.41
-18.96
18.79
Debt-to-EBITDA -0.97
ARRY's Debt-to-EBITDA is ranked lower than
99.99% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. ARRY: -0.97 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ARRY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -12.99  Med: -1.41 Max: 4.67
Current: -0.97
-12.99
4.67
Piotroski F-Score: 4
Altman Z-Score: 5.70
Beneish M-Score: -2.34
WACC vs ROIC
14.66%
145.96%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -63.52
ARRY's Operating Margin % is ranked higher than
56% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. ARRY: -63.52 )
Ranked among companies with meaningful Operating Margin % only.
ARRY' s Operating Margin % Range Over the Past 10 Years
Min: -410.11  Med: -93.28 Max: -12.98
Current: -63.52
-410.11
-12.98
Net Margin % -72.33
ARRY's Net Margin % is ranked higher than
55% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. ARRY: -72.33 )
Ranked among companies with meaningful Net Margin % only.
ARRY' s Net Margin % Range Over the Past 10 Years
Min: -511.63  Med: -83.68 Max: 18.05
Current: -72.33
-511.63
18.05
ROE % -80.48
ARRY's ROE % is ranked lower than
68% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. ARRY: -80.48 )
Ranked among companies with meaningful ROE % only.
ARRY' s ROE % Range Over the Past 10 Years
Min: -3933.07  Med: -132.15 Max: 110.67
Current: -80.48
-3933.07
110.67
ROA % -31.16
ARRY's ROA % is ranked higher than
54% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. ARRY: -31.16 )
Ranked among companies with meaningful ROA % only.
ARRY' s ROA % Range Over the Past 10 Years
Min: -99.03  Med: -51.46 Max: 5.6
Current: -31.16
-99.03
5.6
ROC (Joel Greenblatt) % -1455.76
ARRY's ROC (Joel Greenblatt) % is ranked lower than
64% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. ARRY: -1455.76 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ARRY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1455.76  Med: -321.97 Max: 291.72
Current: -1455.76
-1455.76
291.72
3-Year Revenue Growth Rate 39.40
ARRY's 3-Year Revenue Growth Rate is ranked higher than
85% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ARRY: 39.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ARRY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -35.9  Med: -2.2 Max: 39.8
Current: 39.4
-35.9
39.8
3-Year EBITDA Growth Rate -3.00
ARRY's 3-Year EBITDA Growth Rate is ranked lower than
59% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. ARRY: -3.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ARRY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -2.85 Max: 68.6
Current: -3
0
68.6
3-Year EPS without NRI Growth Rate -1.40
ARRY's 3-Year EPS without NRI Growth Rate is ranked lower than
57% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. ARRY: -1.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ARRY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -2.95 Max: 50.5
Current: -1.4
0
50.5
GuruFocus has detected 2 Warning Signs with Array BioPharma Inc ARRY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ARRY's 30-Y Financials

Financials (Next Earnings Date: 2018-10-31)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

ARRY Guru Trades in Q3 2017

Louis Moore Bacon 100,000 sh (New)
Steven Cohen 9,008,999 sh (+274.44%)
Paul Tudor Jones 75,184 sh (+2.47%)
Ken Fisher 134,180 sh (unchged)
Jim Simons Sold Out
» More
Q4 2017

ARRY Guru Trades in Q4 2017

Pioneer Investments 54,900 sh (New)
Jim Simons 712,671 sh (New)
Ken Fisher 161,433 sh (+20.31%)
Steven Cohen 1,020,900 sh (unchged)
Louis Moore Bacon Sold Out
Steven Cohen 5,712,626 sh (-36.59%)
Paul Tudor Jones 12,834 sh (-82.93%)
» More
Q1 2018

ARRY Guru Trades in Q1 2018

Leon Cooperman 200,000 sh (New)
George Soros 526,500 sh (New)
Paul Tudor Jones 76,307 sh (+494.57%)
Pioneer Investments Sold Out
Ken Fisher 158,223 sh (-1.99%)
Jim Simons 472,952 sh (-33.64%)
Steven Cohen 448,200 sh (-92.15%)
» More
Q2 2018

ARRY Guru Trades in Q2 2018

Leon Cooperman Sold Out
George Soros Sold Out
Steven Cohen Sold Out
Ken Fisher 120,576 sh (-23.79%)
Paul Tudor Jones 41,310 sh (-45.86%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ARRY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-06-30 Reduce -23.79%$13.49 - $19.99 $ 13.80-13%120,576
Leon Cooperman 2018-06-30 Sold Out 0.12%$13.49 - $19.99 $ 13.80-13%0
George Soros 2018-06-30 Sold Out 0.16%$13.49 - $19.99 $ 13.80-13%0
George Soros 2018-03-31 New Buy0.16%$12.59 - $18.4 $ 13.80-14%526,500
Leon Cooperman 2018-03-31 New Buy0.12%$12.59 - $18.4 $ 13.80-14%200,000
Ken Fisher 2018-03-31 Reduce -1.99%$12.59 - $18.4 $ 13.80-14%158,223
Ken Fisher 2017-12-31 Add 20.31%$10.26 - $12.97 $ 13.8021%161,433
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:SZSE:002603, NAS:CBPO, NAS:ONCE, NAS:TSRO, SHSE:600161, SZSE:000990, XSWX:IDIA, NAS:HALO, NAS:IMMU, XBRU:ARGX, XTER:MOR, SZSE:002821, SZSE:300009, XSWX:GALE, NAS:ASND, NAS:FOLD, NYSE:EBS, ROCO:4147, NAS:RARE, NAS:PBYI » details
Traded in other countries:AR2.Germany,
Headquarter Location:USA
Array BioPharma Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.

Array BioPharma Inc was incorporated in Delaware on February 6, 1998. It is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Its clinical stage drugs include Binimetinib, Encorafenib, Selumetinib, Tucatinib/ONT-380, ARRY-382, LOXO-292 and LOXO-195 among others. The company has geographical presence in North America, Europe and Asia Pacific.

Top Ranked Articles about Array BioPharma Inc

Array BioPharma to Report Financial Results for the Fourth Quarter and Full Year of Fiscal 2018 on August 14, 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI™ in combination with MEKTOVI® and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
BRAFTOVI™ (encorafenib) + MEKTOVI® (binimetinib) Receives Positive CHMP Opinion for Advanced BRAF-mutant Melanoma
Market Trends Toward New Normal in Egalet, PPG Industries, Synergy Pharmaceuticals, Equity Residential, Array BioPharma, and Holly Energy Partners — Emerging Consolidated Expectations, Analyst Ratings
Array BioPharma Announces FDA Approval of BRAFTOVI™ (encorafenib) in Combination with MEKTOVI® (binimetinib)
Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO 20th World Congress on Gastrointestinal Cancer
Array BioPharma to Present Overall Survival Results from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the ESMO 20th World Congress on Gastrointestinal Cancer
Array BioPharma Announces Additional Median Overall Survival Results of Encorafenib and Binimetinib in Patients with BRAF-mutant Advanced Melanoma
Array BioPharma To Present at the Jefferies 2018 Global Healthcare Conference
Array BioPharma Announces Oral Presentation from the Pivotal Phase 3 COLUMBUS trial of the Combination of Encorafenib and Binimetinib in Patients with BRAF-mutant Melanoma at 2018 ASCO Annual Meeting

Ratios

vs
industry
vs
history
PB Ratio 10.96
ARRY's PB Ratio is ranked lower than
84% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. ARRY: 10.96 )
Ranked among companies with meaningful PB Ratio only.
ARRY' s PB Ratio Range Over the Past 10 Years
Min: 3.52  Med: 17.7 Max: 135.59
Current: 10.96
3.52
135.59
PS Ratio 15.38
ARRY's PS Ratio is ranked lower than
58% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ARRY: 15.38 )
Ranked among companies with meaningful PS Ratio only.
ARRY' s PS Ratio Range Over the Past 10 Years
Min: 1.44  Med: 7.64 Max: 24.4
Current: 15.38
1.44
24.4
EV-to-EBIT -22.71
ARRY's EV-to-EBIT is ranked lower than
99.99% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. ARRY: -22.71 )
Ranked among companies with meaningful EV-to-EBIT only.
ARRY' s EV-to-EBIT Range Over the Past 10 Years
Min: -43.4  Med: -6 Max: 351.4
Current: -22.71
-43.4
351.4
EV-to-EBITDA -23.17
ARRY's EV-to-EBITDA is ranked lower than
99.99% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. ARRY: -23.17 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARRY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -74.7  Med: -6.55 Max: 173.7
Current: -23.17
-74.7
173.7
EV-to-Revenue 14.98
ARRY's EV-to-Revenue is ranked lower than
53% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. ARRY: 14.98 )
Ranked among companies with meaningful EV-to-Revenue only.
ARRY' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.1  Med: 7.65 Max: 27.9
Current: 14.98
2.1
27.9
Current Ratio 5.73
ARRY's Current Ratio is ranked higher than
59% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. ARRY: 5.73 )
Ranked among companies with meaningful Current Ratio only.
ARRY' s Current Ratio Range Over the Past 10 Years
Min: 0.81  Med: 3.08 Max: 7.86
Current: 5.73
0.81
7.86
Quick Ratio 5.73
ARRY's Quick Ratio is ranked higher than
61% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. ARRY: 5.73 )
Ranked among companies with meaningful Quick Ratio only.
ARRY' s Quick Ratio Range Over the Past 10 Years
Min: 0.81  Med: 3.06 Max: 7.55
Current: 5.73
0.81
7.55
Days Sales Outstanding 93.65
ARRY's Days Sales Outstanding is ranked lower than
72% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. ARRY: 93.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARRY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.61  Med: 50.33 Max: 497.21
Current: 93.65
4.61
497.21
Days Payable 80.31
ARRY's Days Payable is ranked higher than
56% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. ARRY: 80.31 )
Ranked among companies with meaningful Days Payable only.
ARRY' s Days Payable Range Over the Past 10 Years
Min: 37.58  Med: 76.12 Max: 159.87
Current: 80.31
37.58
159.87

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.10
ARRY's 3-Year Average Share Buyback Ratio is ranked higher than
64% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. ARRY: -9.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARRY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -111.3  Med: -11.65 Max: -4.2
Current: -9.1
-111.3
-4.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 14.08
ARRY's Price-to-Net-Cash is ranked lower than
73% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. ARRY: 14.08 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ARRY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.76  Med: 7.69 Max: 141.11
Current: 14.08
2.76
141.11
Price-to-Net-Current-Asset-Value 11.31
ARRY's Price-to-Net-Current-Asset-Value is ranked lower than
72% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. ARRY: 11.31 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ARRY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.24  Med: 7.57 Max: 418.5
Current: 11.31
2.24
418.5
Price-to-Tangible-Book 10.95
ARRY's Price-to-Tangible-Book is ranked lower than
78% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. ARRY: 10.95 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ARRY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.14  Med: 4.71 Max: 123.09
Current: 10.95
1.14
123.09
Price-to-Median-PS-Value 2.01
ARRY's Price-to-Median-PS-Value is ranked lower than
82% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. ARRY: 2.01 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ARRY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.19  Med: 0.91 Max: 2.89
Current: 2.01
0.19
2.89
Earnings Yield (Greenblatt) % -4.43
ARRY's Earnings Yield (Greenblatt) % is ranked higher than
61% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. ARRY: -4.43 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ARRY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -95.2  Med: -13.3 Max: 5
Current: -4.43
-95.2
5

More Statistics

Revenue (TTM) (Mil) $172.11
EPS (TTM) $ -0.68
Beta1.99
Volatility54.87%
52-Week Range $8.50 - 20.21
Shares Outstanding (Mil)210.64

Analyst Estimate

Jun18 Jun19
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.83 -0.82
EPS without NRI ($) -0.83 -0.82
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}